The U.S. Food and Drug Administration (FDA) last month granted Breakthrough Therapy Designation to VER-01, a cannabis-derived, full-spectrum drug for chronic low back pain produced by German company Vertanical. The designation follows two randomized, controlled Phase 3 trials, which demonstrated significant pain reduction, a favorable tolerability profile, and no evidence of dependence. In a direct Phase 3 head-to-head comparator study, […]
The US Food and Drug Administration (FDA) is currently working to understand how cannabis and isolated CBD products can be useful to American citizens. There are robust statistics and stories emerging as the FDA conducts cannabis research. Read more about these details in the following stories, and sign up for our newsletter to be the first to find out when news hits the wire.
